Citation Impact
Citing Papers
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
2011
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
2014
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
2016 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
2019
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes
2013 Standout
Pancreatic cancer
2004 Standout
Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy
2016
Management of borderline and locally advanced pancreatic cancer: Where do we stand?
2014
Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study
2019
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
2004
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Pancreatic cancer
2020 Standout
Rare long-term survivors of pancreatic adenocarcinoma without curative resection
2015
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial
2005
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer
2015
FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
2014
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials
2019
Surgery and chemotherapy for intrahepatic cholangiocarcinoma
2010
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Pancreatic cancer
2016 Standout
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
2016 StandoutNobel
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
2019 Standout
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
2002
Serum Cytokeratin 19 Fragment (CYFRA21-1) as a Prognostic Factor in Intrahepatic Cholangiocarcinoma
2007
Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study
2016
Management of Gallbladder Cancer
2010
Pancreatic Adenocarcinoma
2014 Standout
Progress in research on gold nanoparticles in cancer management
2019 Standout
Acute kidney injury
2019 Standout
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Treatment of unresectable cholangiocarcinoma using yttrium‐90 microspheres
2008
High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy
2020 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
2011
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Pancreatic Cancer
2010 Standout
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Photothermal treatment with EGFRmAb–AuNPs induces apoptosis in hypopharyngeal carcinoma cells via PI3K/AKT/mTOR and DNA damage response pathways
2018
Gallbladder cancer: epidemiology and outcome
2014 Standout
Nanoceria: A Rare-Earth Nanoparticle as a Novel Anti-Angiogenic Therapeutic Agent in Ovarian Cancer
2013
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival
2009
GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study
2007
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy
2016
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
2008
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Pancreatic cancer
2011 Standout
Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study
2002
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
2006
The Role of Gemcitabine in the Treatment of Cholangiocarcinoma and Gallbladder Cancer: A Systematic Review
2005
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review
2009
Diagnosis and management of pancreatic cancer
2013
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
2016
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Emergence of Stereotactic Body Radiation Therapy and Its Impact on Current and Future Clinical Practice
2014
Nephrotoxicity of anticancer treatment
2016
2020 International Society of Hypertension Global Hypertension Practice Guidelines
2020 Standout
Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
2010
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
2010
Works of Frédèric Selle being referenced
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)
2001
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
2016
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study
2004
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study
2009
Weekly Paclitaxel (PAC), Pegylated Liposomal Doxorubicin (PLD) or Topotecan (TOP) ± Bevacizumab (BEV) in Platinum (PT)-Resistant Recurrent Ovarian Cancer (OC): Analysis by Chemotherapy (CT) Cohort in the GCIG Aurelia Randomised Phase III Trial
2012
Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC).
2013
Results of the MARS study on the management of antiangiogenics’ renovascular safety in ovarian cancer.
2013
Wound complications after bevacizumab treatment in patients operated on for ovarian cancer.
2010
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair
2016
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
2007